drugset / Trial / NCT03317717
Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This study will determine the pharmacodynamic and safety of MEDITOXIN® in healthy male volunteers.
Timeline
- Start
- 2017-10-12
- Primary completion
- 2018-01-30
- Completion
- 2018-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 2 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 2 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 5 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 5 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 10 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 10 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 30 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 30 iu | — |
Indications
No indication recorded.